Concepedia

Xiaokun Xiao

XX

10

Publications

1.8K

Citations

10

H-Index

2005

Active since

Affiliations

Ionis Pharmaceuticals (United States)(Current)

Shanghai Jiao Tong University

Memorial Sloan Kettering Cancer Center

The University of Texas MD Anderson Cancer Center

Xiaokun Xiao is an author at Ionis Pharmaceuticals (United States) specializing in tumor microenvironment, cell biology, and medicine.

Top concepts

Publications per year

2005–2019

10

Publications

10

The lncRNA Malat1 Is Dispensable for Mouse Development but Its Transcription Plays a cis-Regulatory Role in the Adult

Bin Zhang, Gayatri Arun, Yuntao S. Mao et al. · Cell Reports · 2012 · 604 citations · Full text

AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer

David S. Hong, Razelle Kurzrock, Youngsoo Kim et al. · Science Translational Medicine · 2015 · 428 citations · Full text

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Matthew J. Reilley, Patricia McCoon, Carl Cook et al. · Journal for ImmunoTherapy of Cancer · 2018 · 275 citations · Full text

Characterization of Target mRNA Reduction Through <i>In Situ</i> RNA Hybridization in Multiple Organ Systems Following Systemic Antisense Treatment in Animals

Gene Hung, Xiaokun Xiao, Raechel Peralta et al. · Nucleic Acid Therapeutics · 2013 · 126 citations

, , +16

Selective Down-Regulation of Glioma-Associated Oncogene 2 Inhibits the Proliferation of Hepatocellular Carcinoma Cells

Youngsoo Kim, Joon Won Yoon, Xiaokun Xiao et al. · Cancer Research · 2007 · 121 citations

, , +16

Rows per page

1–5 of 10